#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Geriatric syndrome refers to a series of symptoms and observations caused by a variety of factors associated with aging , where the older adults show the treatment consciously or otherwise , and long-term care becomes important at the same time .
1-1	0-9	Geriatric	abstract[1]	new[1]	coref	2-4[13_1]
1-2	10-18	syndrome	abstract[1]	new[1]	_	_
1-3	19-25	refers	_	_	_	_
1-4	26-28	to	_	_	_	_
1-5	29-30	a	abstract[2]	new[2]	_	_
1-6	31-37	series	abstract[2]	new[2]	_	_
1-7	38-40	of	abstract[2]	new[2]	_	_
1-8	41-49	symptoms	abstract[2]|abstract	new[2]|new	coref	3-5[27_0]
1-9	50-53	and	abstract[2]	new[2]	_	_
1-10	54-66	observations	abstract[2]|abstract	new[2]|new	_	_
1-11	67-73	caused	_	_	_	_
1-12	74-76	by	_	_	_	_
1-13	77-78	a	abstract[5]	new[5]	_	_
1-14	79-86	variety	abstract[5]	new[5]	_	_
1-15	87-89	of	abstract[5]	new[5]	_	_
1-16	90-97	factors	abstract[5]|abstract	new[5]|new	coref	16-40
1-17	98-108	associated	_	_	_	_
1-18	109-113	with	_	_	_	_
1-19	114-119	aging	abstract	new	_	_
1-20	120-121	,	_	_	_	_
1-21	122-127	where	_	_	_	_
1-22	128-131	the	person[8]	new[8]	coref	12-10[73_8]
1-23	132-137	older	person[8]	new[8]	_	_
1-24	138-144	adults	person[8]	new[8]	_	_
1-25	145-149	show	_	_	_	_
1-26	150-153	the	event[9]	new[9]	coref	4-13[34_9]
1-27	154-163	treatment	event[9]	new[9]	_	_
1-28	164-175	consciously	_	_	_	_
1-29	176-178	or	_	_	_	_
1-30	179-188	otherwise	_	_	_	_
1-31	189-190	,	_	_	_	_
1-32	191-194	and	_	_	_	_
1-33	195-204	long-term	abstract[10]	new[10]	coref	3-17[28_10]
1-34	205-209	care	abstract[10]	new[10]	_	_
1-35	210-217	becomes	_	_	_	_
1-36	218-227	important	_	_	_	_
1-37	228-230	at	_	_	_	_
1-38	231-234	the	time[11]	new[11]	coref	20-14[0_11]
1-39	235-239	same	time[11]	new[11]	_	_
1-40	240-244	time	time[11]	new[11]	_	_
1-41	245-246	.	_	_	_	_

#Text=With respect to geriatric syndrome , often the viewpoint involves the purpose of sustaining the capability for activities of daily living ( ADL ) and improving the quality of life ( QOL ) , rather than just considering the disease condition according to the diagnostic name .
2-1	247-251	With	_	_	_	_
2-2	252-259	respect	abstract[12]	new[12]	_	_
2-3	260-262	to	abstract[12]	new[12]	_	_
2-4	263-272	geriatric	abstract[12]|abstract[13]	new[12]|giv[13]	coref	3-6[0_13]
2-5	273-281	syndrome	abstract[12]|abstract[13]	new[12]|giv[13]	_	_
2-6	282-283	,	_	_	_	_
2-7	284-289	often	_	_	_	_
2-8	290-293	the	abstract[14]	new[14]	_	_
2-9	294-303	viewpoint	abstract[14]	new[14]	_	_
2-10	304-312	involves	_	_	_	_
2-11	313-316	the	abstract[15]	new[15]	_	_
2-12	317-324	purpose	abstract[15]	new[15]	_	_
2-13	325-327	of	_	_	_	_
2-14	328-338	sustaining	_	_	_	_
2-15	339-342	the	abstract[16]	new[16]	_	_
2-16	343-353	capability	abstract[16]	new[16]	_	_
2-17	354-357	for	abstract[16]	new[16]	_	_
2-18	358-368	activities	abstract[16]|abstract[17]	new[16]|new[17]	coref	7-14[50_17]
2-19	369-371	of	abstract[16]|abstract[17]	new[16]|new[17]	_	_
2-20	372-377	daily	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|new[18]	appos	2-23[0_18]
2-21	378-384	living	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|new[18]	_	_
2-22	385-386	(	_	_	_	_
2-23	387-390	ADL	abstract	giv	coref	7-16[51_0]
2-24	391-392	)	_	_	_	_
2-25	393-396	and	_	_	_	_
2-26	397-406	improving	_	_	_	_
2-27	407-410	the	abstract[20]	new[20]	_	_
2-28	411-418	quality	abstract[20]	new[20]	_	_
2-29	419-421	of	abstract[20]	new[20]	_	_
2-30	422-426	life	abstract[20]|abstract	new[20]|new	appos	2-32
2-31	427-428	(	_	_	_	_
2-32	429-432	QOL	abstract	giv	_	_
2-33	433-434	)	_	_	_	_
2-34	435-436	,	_	_	_	_
2-35	437-443	rather	_	_	_	_
2-36	444-448	than	_	_	_	_
2-37	449-453	just	_	_	_	_
2-38	454-465	considering	_	_	_	_
2-39	466-469	the	abstract[24]	new[24]	_	_
2-40	470-477	disease	abstract|abstract[24]	new|new[24]	coref	16-45
2-41	478-487	condition	abstract[24]	new[24]	_	_
2-42	488-497	according	abstract[24]	new[24]	_	_
2-43	498-500	to	abstract[24]	new[24]	_	_
2-44	501-504	the	abstract[24]|abstract[25]	new[24]|new[25]	_	_
2-45	505-515	diagnostic	abstract[24]|abstract[25]	new[24]|new[25]	_	_
2-46	516-520	name	abstract[24]|abstract[25]	new[24]|new[25]	_	_
2-47	521-522	.	_	_	_	_

#Text=Notably , there are geriatric syndrome symptoms that are more frequent and are largely affected by long-term care , such as , disorders associated with mobility ( remain secluded , or bedridden ) , falls , incontinence , and cognitive impairment .
3-1	523-530	Notably	_	_	_	_
3-2	531-532	,	_	_	_	_
3-3	533-538	there	_	_	_	_
3-4	539-542	are	_	_	_	_
3-5	543-552	geriatric	abstract[27]	giv[27]	_	_
3-6	553-561	syndrome	abstract|abstract[27]	giv|giv[27]	_	_
3-7	562-570	symptoms	abstract[27]	giv[27]	_	_
3-8	571-575	that	_	_	_	_
3-9	576-579	are	_	_	_	_
3-10	580-584	more	_	_	_	_
3-11	585-593	frequent	_	_	_	_
3-12	594-597	and	_	_	_	_
3-13	598-601	are	_	_	_	_
3-14	602-609	largely	_	_	_	_
3-15	610-618	affected	_	_	_	_
3-16	619-621	by	_	_	_	_
3-17	622-631	long-term	abstract[28]	giv[28]	coref	5-20[41_28]
3-18	632-636	care	abstract[28]	giv[28]	_	_
3-19	637-638	,	abstract[28]	giv[28]	_	_
3-20	639-643	such	abstract[28]	giv[28]	_	_
3-21	644-646	as	abstract[28]	giv[28]	_	_
3-22	647-648	,	abstract[28]	giv[28]	_	_
3-23	649-658	disorders	abstract[28]|abstract	giv[28]|new	ana	4-1
3-24	659-669	associated	_	_	_	_
3-25	670-674	with	_	_	_	_
3-26	675-683	mobility	abstract	new	_	_
3-27	684-685	(	_	_	_	_
3-28	686-692	remain	_	_	_	_
3-29	693-701	secluded	_	_	_	_
3-30	702-703	,	_	_	_	_
3-31	704-706	or	_	_	_	_
3-32	707-716	bedridden	_	_	_	_
3-33	717-718	)	_	_	_	_
3-34	719-720	,	_	_	_	_
3-35	721-726	falls	_	_	_	_
3-36	727-728	,	_	_	_	_
3-37	729-741	incontinence	_	_	_	_
3-38	742-743	,	_	_	_	_
3-39	744-747	and	_	_	_	_
3-40	748-757	cognitive	_	_	_	_
3-41	758-768	impairment	_	_	_	_
3-42	769-770	.	_	_	_	_

#Text=These are considered issues for which early measures should be incorporated into geriatric treatment .
4-1	771-776	These	abstract	giv	coref	12-34[80_0]
4-2	777-780	are	_	_	_	_
4-3	781-791	considered	_	_	_	_
4-4	792-798	issues	abstract	new	_	_
4-5	799-802	for	_	_	_	_
4-6	803-808	which	_	_	_	_
4-7	809-814	early	abstract[33]	new[33]	coref	5-5[36_33]
4-8	815-823	measures	abstract[33]	new[33]	_	_
4-9	824-830	should	_	_	_	_
4-10	831-833	be	_	_	_	_
4-11	834-846	incorporated	_	_	_	_
4-12	847-851	into	_	_	_	_
4-13	852-861	geriatric	event[34]	giv[34]	coref	18-15[0_34]
4-14	862-871	treatment	event[34]	giv[34]	_	_
4-15	872-873	.	_	_	_	_

#Text=In recent years , measures against frailty and sarcopenia , which elevate the risk of increasing the need for long-term care , are being considered important .
5-1	874-876	In	_	_	_	_
5-2	877-883	recent	time[35]	new[35]	_	_
5-3	884-889	years	time[35]	new[35]	_	_
5-4	890-891	,	_	_	_	_
5-5	892-900	measures	abstract[36]	giv[36]	coref	18-10[126_36]
5-6	901-908	against	abstract[36]	giv[36]	_	_
5-7	909-916	frailty	abstract[36]|abstract	giv[36]|new	coref	6-1
5-8	917-920	and	abstract[36]	giv[36]	_	_
5-9	921-931	sarcopenia	abstract[36]|abstract	giv[36]|new	coref	14-2
5-10	932-933	,	_	_	_	_
5-11	934-939	which	_	_	_	_
5-12	940-947	elevate	_	_	_	_
5-13	948-951	the	abstract[39]	new[39]	coref	7-7[48_39]
5-14	952-956	risk	abstract[39]	new[39]	_	_
5-15	957-959	of	_	_	_	_
5-16	960-970	increasing	_	_	_	_
5-17	971-974	the	abstract[40]	new[40]	coref	7-21[53_40]
5-18	975-979	need	abstract[40]	new[40]	_	_
5-19	980-983	for	abstract[40]	new[40]	_	_
5-20	984-993	long-term	abstract[40]|abstract[41]	new[40]|giv[41]	coref	7-24[54_41]
5-21	994-998	care	abstract[40]|abstract[41]	new[40]|giv[41]	_	_
5-22	999-1000	,	_	_	_	_
5-23	1001-1004	are	_	_	_	_
5-24	1005-1010	being	_	_	_	_
5-25	1011-1021	considered	_	_	_	_
5-26	1022-1031	important	_	_	_	_
5-27	1032-1033	.	_	_	_	_

#Text=Frailty progresses as vulnerability to stress increases due to declining physiological reserves with aging , making one prone to unhealthy conditions .
6-1	1034-1041	Frailty	abstract	giv	coref	8-1
6-2	1042-1052	progresses	_	_	_	_
6-3	1053-1055	as	_	_	_	_
6-4	1056-1069	vulnerability	_	_	_	_
6-5	1070-1072	to	_	_	_	_
6-6	1073-1079	stress	abstract	new	ana	7-1
6-7	1080-1089	increases	_	_	_	_
6-8	1090-1093	due	_	_	_	_
6-9	1094-1096	to	_	_	_	_
6-10	1097-1106	declining	_	_	_	_
6-11	1107-1120	physiological	place[44]	new[44]	_	_
6-12	1121-1129	reserves	place[44]	new[44]	_	_
6-13	1130-1134	with	place[44]	new[44]	_	_
6-14	1135-1140	aging	place[44]	new[44]	_	_
6-15	1141-1142	,	_	_	_	_
6-16	1143-1149	making	_	_	_	_
6-17	1150-1153	one	_	_	_	_
6-18	1154-1159	prone	_	_	_	_
6-19	1160-1162	to	_	_	_	_
6-20	1163-1172	unhealthy	abstract[45]	new[45]	_	_
6-21	1173-1183	conditions	abstract[45]	new[45]	_	_
6-22	1184-1185	.	_	_	_	_

#Text=It is a factor that increases the risk of falling , disabilities in activities of daily living , onset of the need for long-term care , and death .
7-1	1186-1188	It	abstract	giv	coref	7-3[47_0]
7-2	1189-1191	is	_	_	_	_
7-3	1192-1193	a	abstract[47]	giv[47]	_	_
7-4	1194-1200	factor	abstract[47]	giv[47]	_	_
7-5	1201-1205	that	_	_	_	_
7-6	1206-1215	increases	_	_	_	_
7-7	1216-1219	the	abstract[48]	giv[48]	coref	13-19[0_48]
7-8	1220-1224	risk	abstract[48]	giv[48]	_	_
7-9	1225-1227	of	_	_	_	_
7-10	1228-1235	falling	_	_	_	_
7-11	1236-1237	,	_	_	_	_
7-12	1238-1250	disabilities	abstract	new	_	_
7-13	1251-1253	in	_	_	_	_
7-14	1254-1264	activities	abstract[50]	giv[50]	_	_
7-15	1265-1267	of	abstract[50]	giv[50]	_	_
7-16	1268-1273	daily	abstract[50]|abstract[51]	giv[50]|giv[51]	coref	9-9[67_51]
7-17	1274-1280	living	abstract[50]|abstract[51]	giv[50]|giv[51]	_	_
7-18	1281-1282	,	_	_	_	_
7-19	1283-1288	onset	abstract[52]	new[52]	_	_
7-20	1289-1291	of	abstract[52]	new[52]	_	_
7-21	1292-1295	the	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
7-22	1296-1300	need	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
7-23	1301-1304	for	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
7-24	1305-1314	long-term	abstract[52]|abstract[53]|abstract[54]	new[52]|giv[53]|giv[54]	_	_
7-25	1315-1319	care	abstract[52]|abstract[53]|abstract[54]	new[52]|giv[53]|giv[54]	_	_
7-26	1320-1321	,	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
7-27	1322-1325	and	abstract[52]|abstract[53]	new[52]|giv[53]	_	_
7-28	1326-1331	death	abstract[52]|abstract[53]|event	new[52]|giv[53]|new	ana	9-1
7-29	1332-1333	.	_	_	_	_

#Text=Frailty as a concept includes not only physical problems , such as the representative decline in muscle strength , but also mental and physical problems , such as cognitive impairment and depression .
8-1	1334-1341	Frailty	abstract	giv	coref	11-1
8-2	1342-1344	as	_	_	_	_
8-3	1345-1346	a	abstract[57]	new[57]	_	_
8-4	1347-1354	concept	abstract[57]	new[57]	_	_
8-5	1355-1363	includes	_	_	_	_
8-6	1364-1367	not	_	_	_	_
8-7	1368-1372	only	abstract[58]	new[58]	_	_
8-8	1373-1381	physical	abstract[58]	new[58]	_	_
8-9	1382-1390	problems	abstract[58]	new[58]	_	_
8-10	1391-1392	,	abstract[58]	new[58]	_	_
8-11	1393-1397	such	abstract[58]	new[58]	_	_
8-12	1398-1400	as	abstract[58]	new[58]	_	_
8-13	1401-1404	the	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-14	1405-1419	representative	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-15	1420-1427	decline	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-16	1428-1430	in	abstract[58]|abstract[59]	new[58]|new[59]	_	_
8-17	1431-1437	muscle	abstract[58]|abstract[59]|object|abstract[61]	new[58]|new[59]|new|new[61]	coref|coref	14-17|16-30[112_61]
8-18	1438-1446	strength	abstract[58]|abstract[59]|abstract[61]	new[58]|new[59]|new[61]	_	_
8-19	1447-1448	,	_	_	_	_
8-20	1449-1452	but	_	_	_	_
8-21	1453-1457	also	_	_	_	_
8-22	1458-1464	mental	abstract[62]	new[62]	coref	9-4[66_62]
8-23	1465-1468	and	abstract[62]	new[62]	_	_
8-24	1469-1477	physical	abstract[62]	new[62]	_	_
8-25	1478-1486	problems	abstract[62]	new[62]	_	_
8-26	1487-1488	,	abstract[62]	new[62]	_	_
8-27	1489-1493	such	abstract[62]	new[62]	_	_
8-28	1494-1496	as	abstract[62]	new[62]	_	_
8-29	1497-1506	cognitive	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-30	1507-1517	impairment	abstract[62]|abstract[63]	new[62]|new[63]	_	_
8-31	1518-1521	and	abstract[62]	new[62]	_	_
8-32	1522-1532	depression	abstract[62]|abstract	new[62]|new	_	_
8-33	1533-1534	.	_	_	_	_

#Text=It also includes social problems , such as solitary living and economic distress .
9-1	1535-1537	It	event	giv	_	_
9-2	1538-1542	also	_	_	_	_
9-3	1543-1551	includes	_	_	_	_
9-4	1552-1558	social	abstract[66]	giv[66]	_	_
9-5	1559-1567	problems	abstract[66]	giv[66]	_	_
9-6	1568-1569	,	abstract[66]	giv[66]	_	_
9-7	1570-1574	such	abstract[66]	giv[66]	_	_
9-8	1575-1577	as	abstract[66]	giv[66]	_	_
9-9	1578-1586	solitary	abstract[66]|abstract[67]	giv[66]|giv[67]	_	_
9-10	1587-1593	living	abstract[66]|abstract[67]	giv[66]|giv[67]	_	_
9-11	1594-1597	and	abstract[66]	giv[66]	_	_
9-12	1598-1606	economic	abstract[66]|abstract[68]	giv[66]|new[68]	ana	10-3[0_68]
9-13	1607-1615	distress	abstract[66]|abstract[68]	giv[66]|new[68]	_	_
9-14	1616-1617	.	_	_	_	_

#Text=Accordingly , it needs to be considered comprehensively .
10-1	1618-1629	Accordingly	_	_	_	_
10-2	1630-1631	,	_	_	_	_
10-3	1632-1634	it	abstract	giv	_	_
10-4	1635-1640	needs	_	_	_	_
10-5	1641-1643	to	_	_	_	_
10-6	1644-1646	be	_	_	_	_
10-7	1647-1657	considered	_	_	_	_
10-8	1658-1673	comprehensively	_	_	_	_
10-9	1674-1675	.	_	_	_	_

#Text=Frailty is said to be reversible .
11-1	1676-1683	Frailty	event	giv	ana	12-3
11-2	1684-1686	is	_	_	_	_
11-3	1687-1691	said	_	_	_	_
11-4	1692-1694	to	_	_	_	_
11-5	1695-1697	be	_	_	_	_
11-6	1698-1708	reversible	_	_	_	_
11-7	1709-1710	.	_	_	_	_

#Text=Therefore , it is expected that appropriate intervention for frail older adults will lead to improvements in physical function and daily living capabilities , help reverse frailty , and prevent the onset of functional disorders .
12-1	1711-1720	Therefore	_	_	_	_
12-2	1721-1722	,	_	_	_	_
12-3	1723-1725	it	event	giv	coref	12-26[78_0]
12-4	1726-1728	is	_	_	_	_
12-5	1729-1737	expected	_	_	_	_
12-6	1738-1742	that	_	_	_	_
12-7	1743-1754	appropriate	event[72]	new[72]	coref	19-11[135_72]
12-8	1755-1767	intervention	event[72]	new[72]	_	_
12-9	1768-1771	for	event[72]	new[72]	_	_
12-10	1772-1777	frail	event[72]|person[73]	new[72]|giv[73]	coref	19-7[133_73]
12-11	1778-1783	older	event[72]|person[73]	new[72]|giv[73]	_	_
12-12	1784-1790	adults	event[72]|person[73]	new[72]|giv[73]	_	_
12-13	1791-1795	will	_	_	_	_
12-14	1796-1800	lead	_	_	_	_
12-15	1801-1803	to	_	_	_	_
12-16	1804-1816	improvements	abstract[74]	new[74]	_	_
12-17	1817-1819	in	abstract[74]	new[74]	_	_
12-18	1820-1828	physical	abstract[74]|abstract[75]	new[74]|new[75]	coref	16-35[0_75]
12-19	1829-1837	function	abstract[74]|abstract[75]	new[74]|new[75]	_	_
12-20	1838-1841	and	abstract[74]	new[74]	_	_
12-21	1842-1847	daily	abstract[74]|abstract[76]	new[74]|new[76]	_	_
12-22	1848-1854	living	abstract[74]|abstract[76]	new[74]|new[76]	_	_
12-23	1855-1867	capabilities	abstract[74]|abstract[76]	new[74]|new[76]	_	_
12-24	1868-1869	,	_	_	_	_
12-25	1870-1874	help	_	_	_	_
12-26	1875-1882	reverse	event|abstract[78]	new|giv[78]	coref	13-6[0_78]
12-27	1883-1890	frailty	abstract[78]	giv[78]	_	_
12-28	1891-1892	,	_	_	_	_
12-29	1893-1896	and	_	_	_	_
12-30	1897-1904	prevent	_	_	_	_
12-31	1905-1908	the	event[79]	new[79]	_	_
12-32	1909-1914	onset	event[79]	new[79]	_	_
12-33	1915-1917	of	event[79]	new[79]	_	_
12-34	1918-1928	functional	event[79]|abstract[80]	new[79]|giv[80]	_	_
12-35	1929-1938	disorders	event[79]|abstract[80]	new[79]|giv[80]	_	_
12-36	1939-1940	.	_	_	_	_

#Text=For prevention and improvement of frailty , the key points will be active promotion of early identification of risk and desirable interventions as early measures .
13-1	1941-1944	For	_	_	_	_
13-2	1945-1955	prevention	abstract|abstract[82]	new|new[82]	coref|coref	18-12[127_0]|23-15[169_82]
13-3	1956-1959	and	abstract[82]	new[82]	_	_
13-4	1960-1971	improvement	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-5	1972-1974	of	abstract[82]|abstract[83]	new[82]|new[83]	_	_
13-6	1975-1982	frailty	abstract[82]|abstract[83]|abstract	new[82]|new[83]|giv	coref	22-13
13-7	1983-1984	,	_	_	_	_
13-8	1985-1988	the	event[85]	new[85]	coref	13-13[86_85]
13-9	1989-1992	key	event[85]	new[85]	_	_
13-10	1993-1999	points	event[85]	new[85]	_	_
13-11	2000-2004	will	_	_	_	_
13-12	2005-2007	be	_	_	_	_
13-13	2008-2014	active	event[86]	giv[86]	_	_
13-14	2015-2024	promotion	event[86]	giv[86]	_	_
13-15	2025-2027	of	event[86]	giv[86]	_	_
13-16	2028-2033	early	event[86]|abstract[87]	giv[86]|new[87]	_	_
13-17	2034-2048	identification	event[86]|abstract[87]	giv[86]|new[87]	_	_
13-18	2049-2051	of	event[86]|abstract[87]	giv[86]|new[87]	_	_
13-19	2052-2056	risk	event[86]|abstract[87]|abstract	giv[86]|new[87]|giv	_	_
13-20	2057-2060	and	event[86]|abstract[87]	giv[86]|new[87]	_	_
13-21	2061-2070	desirable	event[86]|abstract[87]|event[89]	giv[86]|new[87]|new[89]	coref	20-6[141_89]
13-22	2071-2084	interventions	event[86]|abstract[87]|event[89]	giv[86]|new[87]|new[89]	_	_
13-23	2085-2087	as	event[86]|abstract[87]|event[89]	giv[86]|new[87]|new[89]	_	_
13-24	2088-2093	early	event[86]|abstract[87]|event[89]	giv[86]|new[87]|new[89]	_	_
13-25	2094-2102	measures	event[86]|abstract[87]|event[89]	giv[86]|new[87]|new[89]	_	_
13-26	2103-2104	.	_	_	_	_

#Text=“ Sarcopenia ” is a coined word , where “ sarx ( sarco ) ” means muscle and “ penia ” means “ loss and reduction ” in Greek , and it was first proposed by Rosenberg in 1989 .
14-1	2105-2106	“	_	_	_	_
14-2	2107-2117	Sarcopenia	abstract	giv	coref	14-5[91_0]
14-3	2118-2119	”	_	_	_	_
14-4	2120-2122	is	_	_	_	_
14-5	2123-2124	a	abstract[91]	giv[91]	coref	16-6[105_91]
14-6	2125-2131	coined	abstract[91]	giv[91]	_	_
14-7	2132-2136	word	abstract[91]	giv[91]	_	_
14-8	2137-2138	,	_	_	_	_
14-9	2139-2144	where	_	_	_	_
14-10	2145-2146	“	_	_	_	_
14-11	2147-2151	sarx	_	_	_	_
14-12	2152-2153	(	_	_	_	_
14-13	2154-2159	sarco	_	_	_	_
14-14	2160-2161	)	_	_	_	_
14-15	2162-2163	”	_	_	_	_
14-16	2164-2169	means	_	_	_	_
14-17	2170-2176	muscle	object	giv	coref	15-15
14-18	2177-2180	and	_	_	_	_
14-19	2181-2182	“	_	_	_	_
14-20	2183-2188	penia	_	_	_	_
14-21	2189-2190	”	_	_	_	_
14-22	2191-2196	means	_	_	_	_
14-23	2197-2198	“	_	_	_	_
14-24	2199-2203	loss	abstract	new	coref	16-33[115_0]
14-25	2204-2207	and	_	_	_	_
14-26	2208-2217	reduction	abstract	new	ana	14-32
14-27	2218-2219	”	_	_	_	_
14-28	2220-2222	in	_	_	_	_
14-29	2223-2228	Greek	person	new	_	_
14-30	2229-2230	,	_	_	_	_
14-31	2231-2234	and	_	_	_	_
14-32	2235-2237	it	abstract	giv	ana	15-3
14-33	2238-2241	was	_	_	_	_
14-34	2242-2247	first	_	_	_	_
14-35	2248-2256	proposed	_	_	_	_
14-36	2257-2259	by	_	_	_	_
14-37	2260-2269	Rosenberg	person	new	_	_
14-38	2270-2272	in	_	_	_	_
14-39	2273-2277	1989	time	new	_	_
14-40	2278-2279	.	_	_	_	_

#Text=Originally , it had a strong physiological nuance of decrease ( atrophy ) in muscle mass with aging .
15-1	2280-2290	Originally	_	_	_	_
15-2	2291-2292	,	_	_	_	_
15-3	2293-2295	it	abstract	giv	coref	16-24[108_0]
15-4	2296-2299	had	_	_	_	_
15-5	2300-2301	a	abstract[100]	new[100]	_	_
15-6	2302-2308	strong	abstract[100]	new[100]	_	_
15-7	2309-2322	physiological	abstract[100]	new[100]	_	_
15-8	2323-2329	nuance	abstract[100]	new[100]	_	_
15-9	2330-2332	of	abstract[100]	new[100]	_	_
15-10	2333-2341	decrease	abstract[100]|event	new[100]|new	_	_
15-11	2342-2343	(	_	_	_	_
15-12	2344-2351	atrophy	abstract	new	_	_
15-13	2352-2353	)	_	_	_	_
15-14	2354-2356	in	_	_	_	_
15-15	2357-2363	muscle	object|quantity[104]	giv|new[104]	coref|coref	16-27|16-27[110_104]
15-16	2364-2368	mass	quantity[104]	new[104]	_	_
15-17	2369-2373	with	quantity[104]	new[104]	_	_
15-18	2374-2379	aging	quantity[104]	new[104]	_	_
15-19	2380-2381	.	_	_	_	_

#Text=However , in addition to primary ( aging ) sarcopenia , a broader definition is taking hold , which includes as secondary sarcopenia the reduction in muscle mass and muscle strength and further muscle function loss , due to factors associated with activity , disease , and nutrition .
16-1	2382-2389	However	_	_	_	_
16-2	2390-2391	,	_	_	_	_
16-3	2392-2394	in	_	_	_	_
16-4	2395-2403	addition	_	_	_	_
16-5	2404-2406	to	_	_	_	_
16-6	2407-2414	primary	abstract[105]	giv[105]	coref	17-4[0_105]
16-7	2415-2416	(	abstract[105]	giv[105]	_	_
16-8	2417-2422	aging	abstract[105]	giv[105]	_	_
16-9	2423-2424	)	abstract[105]	giv[105]	_	_
16-10	2425-2435	sarcopenia	abstract[105]	giv[105]	_	_
16-11	2436-2437	,	_	_	_	_
16-12	2438-2439	a	abstract[106]	new[106]	_	_
16-13	2440-2447	broader	abstract[106]	new[106]	_	_
16-14	2448-2458	definition	abstract[106]	new[106]	_	_
16-15	2459-2461	is	_	_	_	_
16-16	2462-2468	taking	_	_	_	_
16-17	2469-2473	hold	abstract	new	_	_
16-18	2474-2475	,	_	_	_	_
16-19	2476-2481	which	_	_	_	_
16-20	2482-2490	includes	_	_	_	_
16-21	2491-2493	as	_	_	_	_
16-22	2494-2503	secondary	_	_	_	_
16-23	2504-2514	sarcopenia	_	_	_	_
16-24	2515-2518	the	abstract[108]	giv[108]	_	_
16-25	2519-2528	reduction	abstract[108]	giv[108]	_	_
16-26	2529-2531	in	abstract[108]	giv[108]	_	_
16-27	2532-2538	muscle	abstract[108]|object|quantity[110]	giv[108]|giv|giv[110]	coref|coref	16-30|24-5[174_110]
16-28	2539-2543	mass	abstract[108]|quantity[110]	giv[108]|giv[110]	_	_
16-29	2544-2547	and	abstract[108]	giv[108]	_	_
16-30	2548-2554	muscle	abstract[108]|object|abstract[112]	giv[108]|giv|giv[112]	coref|coref	16-34|21-27[153_112]
16-31	2555-2563	strength	abstract[108]|abstract[112]	giv[108]|giv[112]	_	_
16-32	2564-2567	and	abstract[108]	giv[108]	_	_
16-33	2568-2575	further	abstract[108]|abstract[115]	giv[108]|giv[115]	_	_
16-34	2576-2582	muscle	abstract[108]|object|abstract[115]	giv[108]|giv|giv[115]	coref	21-27
16-35	2583-2591	function	abstract[108]|abstract|abstract[115]	giv[108]|giv|giv[115]	coref	25-28[194_0]
16-36	2592-2596	loss	abstract[108]|abstract[115]	giv[108]|giv[115]	_	_
16-37	2597-2598	,	abstract[108]|abstract[115]	giv[108]|giv[115]	_	_
16-38	2599-2602	due	abstract[108]|abstract[115]	giv[108]|giv[115]	_	_
16-39	2603-2605	to	abstract[108]|abstract[115]	giv[108]|giv[115]	_	_
16-40	2606-2613	factors	abstract[108]|abstract[115]|abstract	giv[108]|giv[115]|giv	_	_
16-41	2614-2624	associated	_	_	_	_
16-42	2625-2629	with	_	_	_	_
16-43	2630-2638	activity	abstract	new	_	_
16-44	2639-2640	,	_	_	_	_
16-45	2641-2648	disease	abstract	giv	_	_
16-46	2649-2650	,	_	_	_	_
16-47	2651-2654	and	_	_	_	_
16-48	2655-2664	nutrition	abstract	new	_	_
16-49	2665-2666	.	_	_	_	_

#Text=In 2016 , sarcopenia was registered in the International Classification of Diseases ( ICD-10 ) .
17-1	2667-2669	In	_	_	_	_
17-2	2670-2674	2016	time	new	_	_
17-3	2675-2676	,	_	_	_	_
17-4	2677-2687	sarcopenia	abstract	giv	coref	18-20
17-5	2688-2691	was	_	_	_	_
17-6	2692-2702	registered	_	_	_	_
17-7	2703-2705	in	_	_	_	_
17-8	2706-2709	the	abstract[122]	new[122]	appos	17-14[0_122]
17-9	2710-2723	International	abstract[122]	new[122]	_	_
17-10	2724-2738	Classification	abstract[122]	new[122]	_	_
17-11	2739-2741	of	abstract[122]	new[122]	_	_
17-12	2742-2750	Diseases	abstract[122]|abstract	new[122]|new	_	_
17-13	2751-2752	(	_	_	_	_
17-14	2753-2759	ICD-10	abstract	giv	ana	18-1
17-15	2760-2761	)	_	_	_	_
17-16	2762-2763	.	_	_	_	_

#Text=It is now considered as a disease , and measures for the prevention , treatment , and improvement of sarcopenia are urgently needed in the future .
18-1	2764-2766	It	abstract	giv	_	_
18-2	2767-2769	is	_	_	_	_
18-3	2770-2773	now	_	_	_	_
18-4	2774-2784	considered	_	_	_	_
18-5	2785-2787	as	_	_	_	_
18-6	2788-2789	a	_	_	_	_
18-7	2790-2797	disease	_	_	_	_
18-8	2798-2799	,	_	_	_	_
18-9	2800-2803	and	_	_	_	_
18-10	2804-2812	measures	abstract[126]	giv[126]	_	_
18-11	2813-2816	for	abstract[126]	giv[126]	_	_
18-12	2817-2820	the	abstract[126]|abstract[127]	giv[126]|giv[127]	coref	23-15[0_127]
18-13	2821-2831	prevention	abstract[126]|abstract[127]	giv[126]|giv[127]	_	_
18-14	2832-2833	,	abstract[126]	giv[126]	_	_
18-15	2834-2843	treatment	abstract[126]|event	giv[126]|giv	_	_
18-16	2844-2845	,	abstract[126]	giv[126]	_	_
18-17	2846-2849	and	abstract[126]	giv[126]	_	_
18-18	2850-2861	improvement	abstract[126]|abstract[129]	giv[126]|new[129]	coref	23-17[170_129]
18-19	2862-2864	of	abstract[126]|abstract[129]	giv[126]|new[129]	_	_
18-20	2865-2875	sarcopenia	abstract[126]|abstract[129]|abstract	giv[126]|new[129]|giv	ana	19-1
18-21	2876-2879	are	_	_	_	_
18-22	2880-2888	urgently	_	_	_	_
18-23	2889-2895	needed	_	_	_	_
18-24	2896-2898	in	_	_	_	_
18-25	2899-2902	the	time[131]	new[131]	_	_
18-26	2903-2909	future	time[131]	new[131]	_	_
18-27	2910-2911	.	_	_	_	_

#Text=It has been reported that in frail older adults , exercise intervention is effective in improving physical functions , including gait speed .
19-1	2912-2914	It	abstract	giv	coref	23-19
19-2	2915-2918	has	_	_	_	_
19-3	2919-2923	been	_	_	_	_
19-4	2924-2932	reported	_	_	_	_
19-5	2933-2937	that	_	_	_	_
19-6	2938-2940	in	_	_	_	_
19-7	2941-2946	frail	person[133]	giv[133]	coref	21-30[154_133]
19-8	2947-2952	older	person[133]	giv[133]	_	_
19-9	2953-2959	adults	person[133]	giv[133]	_	_
19-10	2960-2961	,	_	_	_	_
19-11	2962-2970	exercise	abstract|event[135]	new|giv[135]	coref|coref	20-6[140_135]|21-8
19-12	2971-2983	intervention	event[135]	giv[135]	_	_
19-13	2984-2986	is	_	_	_	_
19-14	2987-2996	effective	_	_	_	_
19-15	2997-2999	in	_	_	_	_
19-16	3000-3009	improving	_	_	_	_
19-17	3010-3018	physical	abstract[136]	new[136]	_	_
19-18	3019-3028	functions	abstract[136]	new[136]	_	_
19-19	3029-3030	,	abstract[136]	new[136]	_	_
19-20	3031-3040	including	abstract[136]	new[136]	_	_
19-21	3041-3045	gait	abstract[136]|abstract|abstract[138]	new[136]|new|new[138]	_	_
19-22	3046-3051	speed	abstract[136]|abstract[138]	new[136]|new[138]	_	_
19-23	3052-3053	.	_	_	_	_

#Text=However , the effects of the recommended specific event , frequency , and time have not been clarified .
20-1	3054-3061	However	_	_	_	_
20-2	3062-3063	,	_	_	_	_
20-3	3064-3067	the	abstract[139]	new[139]	_	_
20-4	3068-3075	effects	abstract[139]	new[139]	_	_
20-5	3076-3078	of	abstract[139]	new[139]	_	_
20-6	3079-3082	the	abstract[139]|event[140]|event[141]	new[139]|giv[140]|giv[141]	coref	22-6[0_141]
20-7	3083-3094	recommended	abstract[139]|event[140]|event[141]	new[139]|giv[140]|giv[141]	_	_
20-8	3095-3103	specific	abstract[139]|event[140]|event[141]	new[139]|giv[140]|giv[141]	_	_
20-9	3104-3109	event	abstract[139]|event[140]|event[141]	new[139]|giv[140]|giv[141]	_	_
20-10	3110-3111	,	abstract[139]|event[141]	new[139]|giv[141]	_	_
20-11	3112-3121	frequency	abstract[139]|event[141]|abstract	new[139]|giv[141]|new	coref	26-13
20-12	3122-3123	,	abstract[139]|event[141]	new[139]|giv[141]	_	_
20-13	3124-3127	and	abstract[139]|event[141]	new[139]|giv[141]	_	_
20-14	3128-3132	time	abstract[139]|event[141]|time	new[139]|giv[141]|giv	_	_
20-15	3133-3137	have	_	_	_	_
20-16	3138-3141	not	_	_	_	_
20-17	3142-3146	been	_	_	_	_
20-18	3147-3156	clarified	_	_	_	_
20-19	3157-3158	.	_	_	_	_

#Text=In addition to strength training , multifaceted exercise programs that incorporate flexible exercise , balance exercise , and aerobic exercise have also been reported to improve muscle strength in frail older adults .
21-1	3159-3161	In	_	_	_	_
21-2	3162-3170	addition	_	_	_	_
21-3	3171-3173	to	_	_	_	_
21-4	3174-3182	strength	_	_	_	_
21-5	3183-3191	training	abstract	new	coref	23-1[164_0]
21-6	3192-3193	,	_	_	_	_
21-7	3194-3206	multifaceted	abstract[146]	new[146]	_	_
21-8	3207-3215	exercise	abstract|abstract[146]	giv|new[146]	coref	21-12[147_0]
21-9	3216-3224	programs	abstract[146]	new[146]	_	_
21-10	3225-3229	that	_	_	_	_
21-11	3230-3241	incorporate	_	_	_	_
21-12	3242-3250	flexible	abstract[147]	giv[147]	coref	21-15[149_147]
21-13	3251-3259	exercise	abstract[147]	giv[147]	_	_
21-14	3260-3261	,	_	_	_	_
21-15	3262-3269	balance	abstract|abstract[149]	new|giv[149]	coref	21-19[151_149]
21-16	3270-3278	exercise	abstract[149]	giv[149]	_	_
21-17	3279-3280	,	_	_	_	_
21-18	3281-3284	and	_	_	_	_
21-19	3285-3292	aerobic	abstract|abstract[151]	new|giv[151]	coref	25-7[0_151]
21-20	3293-3301	exercise	abstract[151]	giv[151]	_	_
21-21	3302-3306	have	_	_	_	_
21-22	3307-3311	also	_	_	_	_
21-23	3312-3316	been	_	_	_	_
21-24	3317-3325	reported	_	_	_	_
21-25	3326-3328	to	_	_	_	_
21-26	3329-3336	improve	_	_	_	_
21-27	3337-3343	muscle	object|abstract[153]	giv|giv[153]	ana|coref	22-1[0_153]|22-18
21-28	3344-3352	strength	abstract[153]	giv[153]	_	_
21-29	3353-3355	in	_	_	_	_
21-30	3356-3361	frail	person[154]	giv[154]	coref	24-12[177_154]
21-31	3362-3367	older	person[154]	giv[154]	_	_
21-32	3368-3374	adults	person[154]	giv[154]	_	_
21-33	3375-3376	.	_	_	_	_

#Text=It has been suggested that interventions focused on the physical elements behind frailty ( weight loss , muscle weakness , exhaustion , slowness , low physical activity ) are effective , and comprehensive interventions incorporating as many of the elements as possible are desirable .
22-1	3377-3379	It	abstract	giv	coref	24-9[176_0]
22-2	3380-3383	has	_	_	_	_
22-3	3384-3388	been	_	_	_	_
22-4	3389-3398	suggested	_	_	_	_
22-5	3399-3403	that	_	_	_	_
22-6	3404-3417	interventions	event	giv	coref	22-33[161_0]
22-7	3418-3425	focused	_	_	_	_
22-8	3426-3428	on	_	_	_	_
22-9	3429-3432	the	abstract[157]	new[157]	coref	22-39[162_157]
22-10	3433-3441	physical	abstract[157]	new[157]	_	_
22-11	3442-3450	elements	abstract[157]	new[157]	_	_
22-12	3451-3457	behind	abstract[157]	new[157]	_	_
22-13	3458-3465	frailty	abstract[157]|abstract	new[157]|giv	_	_
22-14	3466-3467	(	_	_	_	_
22-15	3468-3474	weight	place	new	_	_
22-16	3475-3479	loss	_	_	_	_
22-17	3480-3481	,	_	_	_	_
22-18	3482-3488	muscle	object	giv	coref	24-6
22-19	3489-3497	weakness	_	_	_	_
22-20	3498-3499	,	_	_	_	_
22-21	3500-3510	exhaustion	_	_	_	_
22-22	3511-3512	,	_	_	_	_
22-23	3513-3521	slowness	_	_	_	_
22-24	3522-3523	,	_	_	_	_
22-25	3524-3527	low	_	_	_	_
22-26	3528-3536	physical	_	_	_	_
22-27	3537-3545	activity	_	_	_	_
22-28	3546-3547	)	_	_	_	_
22-29	3548-3551	are	_	_	_	_
22-30	3552-3561	effective	_	_	_	_
22-31	3562-3563	,	_	_	_	_
22-32	3564-3567	and	_	_	_	_
22-33	3568-3581	comprehensive	event[161]	giv[161]	coref	23-8[0_161]
22-34	3582-3595	interventions	event[161]	giv[161]	_	_
22-35	3596-3609	incorporating	_	_	_	_
22-36	3610-3612	as	_	_	_	_
22-37	3613-3617	many	_	_	_	_
22-38	3618-3620	of	_	_	_	_
22-39	3621-3624	the	abstract[162]	giv[162]	_	_
22-40	3625-3633	elements	abstract[162]	giv[162]	_	_
22-41	3634-3636	as	_	_	_	_
22-42	3637-3645	possible	_	_	_	_
22-43	3646-3649	are	_	_	_	_
22-44	3650-3659	desirable	_	_	_	_
22-45	3660-3661	.	_	_	_	_

#Text=Resistance training and nutritional ( protein ) interventions are often selected as measures for prevention and improvement of sarcopenia .
23-1	3662-3672	Resistance	abstract|abstract[164]	new|giv[164]	_	_
23-2	3673-3681	training	abstract[164]	giv[164]	_	_
23-3	3682-3685	and	_	_	_	_
23-4	3686-3697	nutritional	substance	new	appos	23-6
23-5	3698-3699	(	_	_	_	_
23-6	3700-3707	protein	substance	giv	coref	27-11
23-7	3708-3709	)	_	_	_	_
23-8	3710-3723	interventions	event	giv	coref	26-12[197_0]
23-9	3724-3727	are	_	_	_	_
23-10	3728-3733	often	_	_	_	_
23-11	3734-3742	selected	_	_	_	_
23-12	3743-3745	as	_	_	_	_
23-13	3746-3754	measures	_	_	_	_
23-14	3755-3758	for	_	_	_	_
23-15	3759-3769	prevention	abstract|abstract[169]	giv|giv[169]	_	_
23-16	3770-3773	and	abstract[169]	giv[169]	_	_
23-17	3774-3785	improvement	abstract[169]|abstract[170]	giv[169]|giv[170]	coref	25-24[192_170]
23-18	3786-3788	of	abstract[169]|abstract[170]	giv[169]|giv[170]	_	_
23-19	3789-3799	sarcopenia	abstract[169]|abstract[170]|abstract	giv[169]|giv[170]|giv	coref	28-19
23-20	3800-3801	.	_	_	_	_

#Text=In a report on increased muscle mass and muscle strength in older adults , a high load of 70 – 80 % of 1 repetition maximum ( RM ) was used .
24-1	3802-3804	In	_	_	_	_
24-2	3805-3806	a	abstract[172]	new[172]	_	_
24-3	3807-3813	report	abstract[172]	new[172]	_	_
24-4	3814-3816	on	abstract[172]	new[172]	_	_
24-5	3817-3826	increased	abstract[172]|quantity[174]	new[172]|giv[174]	coref	27-24[207_174]
24-6	3827-3833	muscle	abstract[172]|object|quantity[174]	new[172]|giv|giv[174]	coref	24-9
24-7	3834-3838	mass	abstract[172]|quantity[174]	new[172]|giv[174]	_	_
24-8	3839-3842	and	abstract[172]	new[172]	_	_
24-9	3843-3849	muscle	abstract[172]|object|abstract[176]	new[172]|giv|giv[176]	ana|coref	25-10[0_176]|25-28
24-10	3850-3858	strength	abstract[172]|abstract[176]	new[172]|giv[176]	_	_
24-11	3859-3861	in	abstract[172]|abstract[176]	new[172]|giv[176]	_	_
24-12	3862-3867	older	abstract[172]|abstract[176]|person[177]	new[172]|giv[176]|giv[177]	coref	25-4[184_177]
24-13	3868-3874	adults	abstract[172]|abstract[176]|person[177]	new[172]|giv[176]|giv[177]	_	_
24-14	3875-3876	,	_	_	_	_
24-15	3877-3878	a	quantity[178]	new[178]	_	_
24-16	3879-3883	high	quantity[178]	new[178]	_	_
24-17	3884-3888	load	quantity[178]	new[178]	_	_
24-18	3889-3891	of	quantity[178]	new[178]	_	_
24-19	3892-3894	70	quantity[178]|quantity	new[178]|new	_	_
24-20	3895-3896	–	quantity[178]	new[178]	_	_
24-21	3897-3899	80	quantity[178]|quantity[180]	new[178]|new[180]	_	_
24-22	3900-3901	%	quantity[178]|quantity[180]	new[178]|new[180]	_	_
24-23	3902-3904	of	quantity[178]|quantity[180]	new[178]|new[180]	_	_
24-24	3905-3906	1	quantity[178]|quantity[180]|quantity[182]	new[178]|new[180]|new[182]	_	_
24-25	3907-3917	repetition	quantity[178]|quantity[180]|event|quantity[182]	new[178]|new[180]|new|new[182]	_	_
24-26	3918-3925	maximum	quantity[178]|quantity[180]|quantity[182]	new[178]|new[180]|new[182]	_	_
24-27	3926-3927	(	_	_	_	_
24-28	3928-3930	RM	person	new	coref	25-25
24-29	3931-3932	)	_	_	_	_
24-30	3933-3936	was	_	_	_	_
24-31	3937-3941	used	_	_	_	_
24-32	3942-3943	.	_	_	_	_

#Text=However , for older adults without exercise habits , it was reported that even with a load of 40 – 50 % of 1 RM improvement in muscle function can be expected .
25-1	3944-3951	However	_	_	_	_
25-2	3952-3953	,	_	_	_	_
25-3	3954-3957	for	_	_	_	_
25-4	3958-3963	older	person[184]	giv[184]	_	_
25-5	3964-3970	adults	person[184]	giv[184]	_	_
25-6	3971-3978	without	person[184]	giv[184]	_	_
25-7	3979-3987	exercise	person[184]|abstract|abstract[186]	giv[184]|giv|new[186]	coref	28-4[210_0]
25-8	3988-3994	habits	person[184]|abstract[186]	giv[184]|new[186]	_	_
25-9	3995-3996	,	_	_	_	_
25-10	3997-3999	it	abstract	giv	coref	27-28[209_0]
25-11	4000-4003	was	_	_	_	_
25-12	4004-4012	reported	_	_	_	_
25-13	4013-4017	that	_	_	_	_
25-14	4018-4022	even	quantity[188]	new[188]	coref	26-3[195_188]
25-15	4023-4027	with	quantity[188]	new[188]	_	_
25-16	4028-4029	a	quantity[188]	new[188]	_	_
25-17	4030-4034	load	quantity[188]	new[188]	_	_
25-18	4035-4037	of	quantity[188]	new[188]	_	_
25-19	4038-4040	40	quantity[188]|quantity	new[188]|new	_	_
25-20	4041-4042	–	quantity[188]	new[188]	_	_
25-21	4043-4045	50	quantity[188]|quantity[190]	new[188]|new[190]	_	_
25-22	4046-4047	%	quantity[188]|quantity[190]	new[188]|new[190]	_	_
25-23	4048-4050	of	quantity[188]|quantity[190]	new[188]|new[190]	_	_
25-24	4051-4052	1	quantity[188]|quantity[190]|abstract[192]	new[188]|new[190]|giv[192]	_	_
25-25	4053-4055	RM	quantity[188]|quantity[190]|person|abstract[192]	new[188]|new[190]|giv|giv[192]	_	_
25-26	4056-4067	improvement	quantity[188]|quantity[190]|abstract[192]	new[188]|new[190]|giv[192]	_	_
25-27	4068-4070	in	quantity[188]|quantity[190]|abstract[192]	new[188]|new[190]|giv[192]	_	_
25-28	4071-4077	muscle	quantity[188]|quantity[190]|abstract[192]|object|abstract[194]	new[188]|new[190]|giv[192]|giv|giv[194]	coref	27-10
25-29	4078-4086	function	quantity[188]|quantity[190]|abstract[192]|abstract[194]	new[188]|new[190]|giv[192]|giv[194]	_	_
25-30	4087-4090	can	_	_	_	_
25-31	4091-4093	be	_	_	_	_
25-32	4094-4102	expected	_	_	_	_
25-33	4103-4104	.	_	_	_	_

#Text=When setting a low load cannot be avoided , long-term and high frequency interventions may be necessary .
26-1	4105-4109	When	_	_	_	_
26-2	4110-4117	setting	_	_	_	_
26-3	4118-4119	a	quantity[195]	giv[195]	_	_
26-4	4120-4123	low	quantity[195]	giv[195]	_	_
26-5	4124-4128	load	quantity[195]	giv[195]	_	_
26-6	4129-4135	cannot	_	_	_	_
26-7	4136-4138	be	_	_	_	_
26-8	4139-4146	avoided	_	_	_	_
26-9	4147-4148	,	_	_	_	_
26-10	4149-4158	long-term	_	_	_	_
26-11	4159-4162	and	_	_	_	_
26-12	4163-4167	high	event[197]	giv[197]	coref	27-3[198_197]
26-13	4168-4177	frequency	place|event[197]	giv|giv[197]	_	_
26-14	4178-4191	interventions	event[197]	giv[197]	_	_
26-15	4192-4195	may	_	_	_	_
26-16	4196-4198	be	_	_	_	_
26-17	4199-4208	necessary	_	_	_	_
26-18	4209-4210	.	_	_	_	_

#Text=Moreover , nutritional interventions for the purpose of promoting muscle protein synthesis ( such as amino acid intake ) are effective in increasing muscle mass and improving muscle strength .
27-1	4211-4219	Moreover	_	_	_	_
27-2	4220-4221	,	_	_	_	_
27-3	4222-4233	nutritional	event[198]	giv[198]	coref	28-4[211_198]
27-4	4234-4247	interventions	event[198]	giv[198]	_	_
27-5	4248-4251	for	event[198]	giv[198]	_	_
27-6	4252-4255	the	event[198]|abstract[199]	giv[198]|new[199]	_	_
27-7	4256-4263	purpose	event[198]|abstract[199]	giv[198]|new[199]	_	_
27-8	4264-4266	of	_	_	_	_
27-9	4267-4276	promoting	_	_	_	_
27-10	4277-4283	muscle	object|abstract[202]	giv|new[202]	coref	27-24
27-11	4284-4291	protein	substance|abstract[202]	giv|new[202]	_	_
27-12	4292-4301	synthesis	abstract[202]	new[202]	_	_
27-13	4302-4303	(	abstract[202]	new[202]	_	_
27-14	4304-4308	such	abstract[202]	new[202]	_	_
27-15	4309-4311	as	abstract[202]	new[202]	_	_
27-16	4312-4317	amino	abstract[202]|substance|event[205]	new[202]|new|new[205]	_	_
27-17	4318-4322	acid	abstract[202]|substance|event[205]	new[202]|new|new[205]	_	_
27-18	4323-4329	intake	abstract[202]|event[205]	new[202]|new[205]	_	_
27-19	4330-4331	)	abstract[202]	new[202]	_	_
27-20	4332-4335	are	_	_	_	_
27-21	4336-4345	effective	_	_	_	_
27-22	4346-4348	in	_	_	_	_
27-23	4349-4359	increasing	_	_	_	_
27-24	4360-4366	muscle	object|quantity[207]	giv|giv[207]	coref	27-28
27-25	4367-4371	mass	quantity[207]	giv[207]	_	_
27-26	4372-4375	and	_	_	_	_
27-27	4376-4385	improving	_	_	_	_
27-28	4386-4392	muscle	object|abstract[209]	giv|giv[209]	_	_
27-29	4393-4401	strength	abstract[209]	giv[209]	_	_
27-30	4402-4403	.	_	_	_	_

#Text=Accordingly , not only exercise interventions but also nutritional interventions undertaken concurrently are expected to be effective against sarcopenia .
28-1	4404-4415	Accordingly	_	_	_	_
28-2	4416-4417	,	_	_	_	_
28-3	4418-4421	not	_	_	_	_
28-4	4422-4426	only	abstract[210]|event[211]	giv[210]|giv[211]	_	_
28-5	4427-4435	exercise	abstract[210]|event[211]	giv[210]|giv[211]	_	_
28-6	4436-4449	interventions	event[211]	giv[211]	_	_
28-7	4450-4453	but	event[211]	giv[211]	_	_
28-8	4454-4458	also	event[211]	giv[211]	_	_
28-9	4459-4470	nutritional	event[211]	giv[211]	_	_
28-10	4471-4484	interventions	event[211]	giv[211]	_	_
28-11	4485-4495	undertaken	_	_	_	_
28-12	4496-4508	concurrently	_	_	_	_
28-13	4509-4512	are	_	_	_	_
28-14	4513-4521	expected	_	_	_	_
28-15	4522-4524	to	_	_	_	_
28-16	4525-4527	be	_	_	_	_
28-17	4528-4537	effective	_	_	_	_
28-18	4538-4545	against	_	_	_	_
28-19	4546-4556	sarcopenia	abstract	giv	_	_
28-20	4557-4558	.	_	_	_	_
